GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance

U.S. Markets close in 3 hrs 10 mins

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
67.60+0.08 (+0.13%)
As of 12:50PM EDT. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close67.51
Bid67.59 x 800
Ask67.60 x 400
Day's Range66.97 - 67.82
52 Week Range65.38 - 103.10
Avg. Volume10,595,578
Market Cap88.35B
PE Ratio (TTM)6.80
Earnings DateN/A
Dividend & Yield2.08 (3.08%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters2 hours ago

    Gilead hepatitis C drug patent faces European challenge

    International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment. Sofosbuvir is sold by the U.S. drugmaker as Sovaldi and is included in other hepatitis C medicines such as Harvoni and Epclusa. The treatment is transforming the fight against the liver-destroying viral disease by offering an effective cure, but Medecins Sans Frontieres (MSF) and Medecins du Monde (MdM) said its high cost was a serious barrier.

  • Investopedia3 hours ago

    Gilead’s Hep C Bestseller Faces Patent Dispute (GILD)

    Sovaldi is facing another patent challenge case in Europe by two international organizations

  • Better Buy: Celgene Corporation vs. Gilead Sciences
    Motley Fool3 hours ago

    Better Buy: Celgene Corporation vs. Gilead Sciences

    Gilead Sciences and Celgene are two of the most successful companies in biotech, but which stock is the better buy right now?